2024 World Conference on Lung Cancer (WCLC) - Posters-P2.10B.02 Cutoff Determination for C-met Protein Overexpression by VENTANA MET (SP44) IHC to Determine Teliso-v Eligibility in NSCLC

P2.10B.02 Cutoff Determination for C-met Protein Overexpression by VENTANA MET (SP44) IHC to Determine Teliso-v Eligibility in NSCLC

Back to course

Pdf Summary

The presentation at the World Conference on Lung Cancer (WCLC) in September 2024 by Nancy Zhang and colleagues from AbbVie Inc. discussed the determination of cutoff values for c-Met protein overexpression using MET (SP44) immunohistochemistry (IHC) to identify patient eligibility for Teliso-V treatment in non-small cell lung cancer (NSCLC). Teliso-V, a c-Met protein-directed antibody-drug conjugate (comprising the monoclonal antibody telisotuzumab and the cytotoxic agent MMAE), has shown promising efficacy in treating heavily pretreated patients with advanced NSCLC expressing c-Met protein.<br /><br />The study retrospectively analyzed tumor samples from patients with epidermal growth factor receptor (EGFR) wild-type non-squamous NSCLC to optimize cutoff values that indicate positive c-Met expression. This involved assessing membrane staining intensity and c-Met staining positivity percentage in tumor cells. Various intensity thresholds (1, 2, and 3) and positivity cutoffs (from 10% to 100%) were evaluated using statistical analyses.<br /><br />Results indicated that at a staining intensity of 3, a cutoff of 25% c-Met-positive tumor cells was most predictive of treatment response, while a cutoff of 50% was significant for indicating high expression of c-Met protein. These results were incorporated into phase 2 and 3 studies, including the LUMINOSITY trial, establishing the prevalence of c-Met overexpression in over 1,950 sampled NSCLC patients. <br /><br />The findings suggest these cutoffs as standards for identifying patients suitable for Teliso-V treatment, with AbbVie acknowledging the support of study participants and sites. The trial was funded by AbbVie, with authors employed by the company, who may have financial interests related to the investigation.

Asset Subtitle

Nancy Zhang

Meta Tag

Speaker Nancy Zhang

Topic Metastatic NSCLC – Cytotoxic Therapy

Keywords

World Conference on Lung Cancer

c-Met protein overexpression

MET (SP44) immunohistochemistry

Teliso-V treatment

non-small cell lung cancer

EGFR wild-type NSCLC

staining intensity

LUMINOSITY trial

AbbVie Inc.

antibody-drug conjugate